Navigation Links
Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
Date:11/19/2007

Vaccines from Wyeth and GlaxoSmithKline Will Also Be Vying to Capture Shares of the Escalating Pneumococcal Vaccine Market, According to a New

Report from Decision Resources

WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the most promising antibiotics in development for the treatment of community-acquired pneumonia are intravenous agents that will be used in the hospital setting, including Johnson & Johnson/Basilea's ceftobiprole and Forest's ceftaroline. The broad spectrum of these next- generation cephalosporins includes activity against methicillin-resistant Staphylococcus aureus.

The new Pharmacor report entitled Community-Acquired Pneumonia finds that in 2006 antibiotics generated more than $800 million while the pneumococcal vaccines garnered approximately $1.5 billion in sales in the major pharmaceutical markets. Decision Resources forecasts that the hospital segment of the community-acquired pneumonia market will experience considerable growth, driven by rising resistance rates that will encourage the uptake of novel products. However, growth in the outpatient market will be limited over the next decade given its maturity, increased availability of generic agents and the upcoming patent expiry of products such as Johnson & Johnson's Levaquin. The launch of vaccines in late-stage development from GlaxoSmithKline and Wyeth expand upon the serotype coverage of Wyeth's blockbuster vaccine, Prevnar, and will drive growth in the pneumococcal vaccine market.

"Community-acquired pneumonia is an important indication for antibiotic drug developers because it represents a sizeable inpatient population and can be a gateway indication to the large outpatient respiratory tract infections market," said Kaitlyn Sullivan, analyst at Decision Resources. "Drug resistance will lead to a shift in prescribing practices in the coming years. Physicians interviewed expressed increasing concern about rising levels of macrolide resistance in the outpatient setting."

About The Report

Community-acquired pneumonia examines the opportunities remaining for new antibiotics, therapeutics, and vaccines in a relatively mature and competitive market, and it describes ways that companies can capitalize on these opportunities. The report examines current therapies, unmet needs, and trends in medical practice that are essential to understanding the community-acquired drug market. It also provides comprehensive coverage of therapeutic agents and vaccines in late-stage development for community-acquired pneumonia and details a forecast covering market segments such as inpatient, outpatient, pediatric vaccine, and adult vaccine segments in seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan).

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
5. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
6. So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
7. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
8. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
9. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
10. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
11. Johnson & Johnson Announces Changes to Accelerate Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):